despit
progress
made
graft
patient
surviv
recent
year
infecti
complic
remain
major
sourc
morbid
mortal
pediatr
solid
organ
transplant
recipi
risk
infect
transplant
determin
interact
sever
factor
includ
age
type
organ
transplant
type
intens
immunosuppress
environment
exposur
consequ
invas
procedur
compar
adult
transplant
recipi
children
higher
risk
develop
primari
infect
variou
organ
transplant
often
lack
previou
immun
natur
exposur
mani
microb
often
complet
primari
immun
seri
time
transplant
articl
provid
overview
risk
factor
time
type
infecti
complic
associ
organ
transplant
children
solid
organ
transplant
sot
major
therapeut
option
mani
children
endstag
organ
failur
almost
pediatr
candid
recipi
organ
transplant
unit
state
advanc
immunosuppress
agent
surgic
techniqu
surviv
rate
continu
improv
despit
progress
made
graft
preserv
patient
surviv
infecti
complic
remain
major
sourc
morbid
mortal
particularli
pediatr
transplant
patient
pediatr
organ
transplant
recipi
differ
adult
counterpart
sever
way
includ
underli
etiolog
organ
failur
complex
surgic
procedur
suscept
posttranspl
complic
particularli
infect
articl
provid
overview
infecti
complic
associ
organ
transplant
children
risk
infect
children
sot
larg
determin
interact
sever
factor
includ
type
intens
immunosuppress
net
state
immunosuppress
environment
exposur
consequ
invas
procedur
factor
predispos
infect
transplant
classifi
present
transplant
relat
transplant
procedur
periop
posttranspl
period
tabl
age
import
determin
suscept
certain
pathogen
diseas
sever
often
young
children
lack
immun
mani
pathogen
transplant
occur
complet
primari
immun
seri
render
suscept
vaccin
prevent
ill
exposur
common
commun
pathogen
accordingli
young
children
compar
adult
transplant
recipi
higher
risk
acquir
primari
infect
mani
organ
immunosuppress
lead
increas
sever
underli
diseas
process
complic
end
stage
organ
diseas
repres
addit
risk
infecti
complic
risk
urinari
tract
infect
uti
renal
transplant
increas
children
underli
vesicoureter
reflux
candid
lung
transplant
cystic
fibrosi
cf
often
colon
fungi
highli
resist
gramneg
bacteria
likewis
prolong
hospit
time
transplant
increas
risk
nosocomi
colon
resist
organ
disord
requir
palli
surgeri
also
lead
technic
difficulti
subsequ
transplant
increas
risk
infect
final
children
previous
immunosuppress
iatrogen
medic
chronic
malnutrit
enhanc
risk
infect
transplant
type
allograft
technic
factor
uniqu
organ
transplant
procedur
import
determin
locat
type
postop
infect
exampl
risk
infect
liver
transplant
associ
type
biliari
reconstruct
use
thrombosi
hepat
arteri
shown
predispos
hepat
abscess
bacteremia
follow
liver
transplant
thorac
transplant
recipi
mediastin
bleed
requir
subsequ
reexplor
increas
risk
mediastin
sepsi
prolong
oper
time
associ
increas
risk
infect
like
surrog
marker
technic
difficulti
surgeri
addit
ischem
injuri
reduc
viabil
allograft
increas
risk
infect
transplant
distinct
effici
mode
transmiss
latent
organ
includ
cellassoci
virus
cmv
ebv
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
chronic
bacteria
mycobacteria
syphili
fungi
histoplasma
coccidioid
cryptococcu
parasit
toxoplasma
gondii
trypanosoma
cruzi
strongyloid
stercorali
graft
advers
consequ
microb
donor
signific
often
consid
absolut
contraind
transplant
eg
hiv
hbv
ubiquit
organ
cmv
ebv
altern
strategi
prevent
diseas
post
transplant
institut
immunosuppress
prolong
use
indwel
cannula
environment
exposur
among
major
determin
risk
infect
follow
transplant
furthermor
interact
sever
factor
includ
natur
immunosuppress
regimen
treatment
reject
neutropenia
metabol
abnorm
ie
hypoalbuminemia
uremia
hyperglycemia
infect
immunomodul
virus
eg
cmv
ebv
determin
overal
state
immunosuppress
individu
transplant
recipi
therefor
risk
infect
immunosuppress
regimen
evolv
specif
natur
infecti
complic
may
also
chang
thu
import
monitor
new
infecti
complic
evalu
novel
immunosuppress
agent
infect
transplant
tend
follow
predict
tempor
pattern
absenc
antimicrobi
intervent
group
three
major
time
frame
earli
intermedi
late
timet
prove
use
differenti
diagnosi
patient
present
possibl
infecti
diseas
syndrom
infect
seen
first
month
transplant
associ
technic
problem
similar
complic
compar
major
surgeri
includ
bacteri
candid
surgic
wound
infect
pneumonia
bacteremia
uti
postop
bacteremia
relat
predominantli
indwel
cathet
also
result
foci
infect
pneumonia
pyelonephr
mediastin
addit
caus
infect
earli
post
transplant
period
clude
pathogen
present
recipi
transplant
may
exacerb
immunosuppress
therapi
herp
simplex
viru
hsv
less
commonli
acut
infect
transmit
contamin
allograft
final
nosocomi
infect
respiratori
virus
influenza
parainfluenza
respiratori
syncyti
viru
rsv
sever
earli
period
transplant
intermedi
period
infect
associ
postop
complic
augment
immunosuppress
develop
reactiv
latent
organ
within
host
graft
associ
infecti
agent
cmv
ebv
gondii
compris
major
infect
seen
time
period
use
prophylaxi
preemptiv
therapi
cmv
modifi
time
diseas
occur
greater
month
transplant
overal
state
immunosuppress
also
promot
permiss
environ
opportunist
infect
pneumocysti
jiroveci
aspergillu
spp
period
less
well
defin
type
infect
seen
larg
depend
transplant
outcom
degre
immunosuppress
accordingli
highest
risk
lifethreaten
opportunist
infect
occur
set
poor
allograft
function
chronic
viral
infect
greater
exposur
immunosuppress
contrast
type
sever
infect
seen
patient
good
allograft
function
lowdos
mainten
immunosuppress
tend
similar
observ
otherwis
healthi
children
commun
acquir
respiratori
virus
infect
occur
time
relat
patient
clinic
immunosuppress
statu
rather
tempor
event
per
se
exampl
children
continu
central
intraven
access
remain
risk
line
associ
infect
regardless
time
post
transplant
hospit
children
risk
health
careassoci
infect
viral
infect
major
caus
morbid
mortal
pediatr
organ
transplant
identif
greatli
aid
avail
newer
molecular
diagnost
techniqu
herpesvirus
cmv
ebv
hsv
varicella
zoster
viru
vzv
less
frequent
import
viral
infect
pediatr
sot
share
abil
establish
lifelong
latenc
lead
intermitt
reactiv
either
spontan
result
variou
stimuli
enhanc
immunosuppress
herpesvirus
aris
primari
infect
commun
graft
associ
reactiv
host
viru
reinfect
new
viral
strain
gener
primari
infect
sot
caus
signific
diseas
unit
state
primari
cmv
infect
occur
first
two
decad
life
asymptomat
infect
infecti
mononucleosislik
syndrom
approxim
popul
cmv
one
import
infecti
complic
sot
widespread
use
prophylaxi
cmv
diseas
report
occur
pediatr
liver
recipi
kidney
recipi
thorac
organ
recipi
last
decad
impact
cmv
infect
diseas
morbid
mortal
reduc
improv
prevent
manag
strategi
sever
risk
factor
develop
cmv
infect
diseas
organ
transplant
recogn
primari
cmv
infect
acquir
donor
allograft
ie
cmv
donorpositiverecipientneg
associ
highest
morbid
mortal
acquisit
cmv
blood
product
significantli
decreas
sinc
era
screen
blood
institut
leukoreduct
pack
red
blood
cell
mani
center
reactiv
endogen
cmv
superinfect
new
cmv
strain
gener
associ
lesser
incid
sever
diseas
due
presenc
cmvspecif
humor
cellmedi
immun
recipi
antithymocyt
globulin
monoclon
antibodi
increas
risk
cmv
diseas
cmv
caus
wide
rang
clinic
manifest
vari
accord
type
allograft
natur
durat
immunosuppress
definit
cmv
infect
diseas
develop
purpos
consist
report
cmv
clinic
trial
cmv
infect
defin
cmv
replic
bodi
fluid
tissu
specimen
cmv
diseas
refer
evid
infect
presenc
attribut
symptom
typic
present
day
transplant
delay
set
prophylaxi
diseas
caus
cmv
classifi
cmv
syndrom
clinic
condit
fever
malais
leukopenia
andor
thrombocytopenia
absenc
end
organ
involv
cmv
tissu
invas
diseas
present
pneumon
hepat
gastrointestin
diseas
myocard
less
frequent
enceph
retin
histolog
examin
involv
organ
necessari
confirm
diagnosi
cmv
invas
diseas
predilect
cmv
invad
allograft
addit
direct
viral
effect
caus
symptomat
diseas
cmv
associ
indirect
immunomodulatori
effect
lead
enhanc
suscept
opportunist
infect
includ
aspergillu
ebvrel
posttranspl
lymphoprolif
diseas
ptld
well
increas
risk
graft
reject
diagnosi
cmv
evolv
recent
year
cmv
serolog
use
determin
donor
recipi
pretranspl
serostatu
posttranspl
risk
limit
valu
transplant
cmv
cultur
varieti
specimen
includ
urin
tissu
respiratori
secret
howev
tradit
cultur
slow
less
sensit
detect
newer
molecular
techniqu
although
rapid
shell
vial
cultur
techniqu
cmv
improv
timeli
detect
neither
cultur
method
abl
distinguish
viral
shed
true
cmv
diseas
antigenemia
assay
detect
late
structur
protein
produc
leukocyt
sensit
specif
need
rapid
process
technic
skill
interpret
limit
use
molecular
diagnost
assay
detect
quantifi
cmvdna
polymeras
chain
reaction
pcr
high
sensit
increasingli
recogn
method
choic
diagnosi
therapeut
monitor
cmv
diseas
compar
studi
antigenemia
detect
pcr
shown
concord
pcr
antigenemia
use
earli
detect
viral
replic
accord
local
experi
approach
prevent
cmv
includ
use
cmv
seroneg
leukocytereduc
blood
product
antivir
agent
immunoglobulin
therapi
specif
prevent
strategi
vari
wide
among
center
two
approach
commonli
use
univers
prophylaxi
patient
risk
cmv
preemptiv
therapi
strategi
advantag
disadvantag
unfortun
data
multicent
control
random
trial
evalu
differ
prevent
strategi
pediatr
transplant
recipi
lack
intraven
ganciclovir
nucleosid
analog
therapi
choic
establish
cmv
diseas
myelotox
limit
side
effect
foscarnet
competit
inhibitor
viral
dna
polymeras
cidofovir
nucleotid
analog
broad
antivir
activ
therapeut
altern
case
ganciclovir
resist
agent
signific
nephrotox
oral
agent
oral
ganciclovir
recent
ganciclovir
prodrug
valganciclovir
use
often
prophylaxi
preemptiv
therapi
appropri
dose
valganciclovir
children
still
known
benefit
ongo
multicent
intern
studi
pharmacolog
liquid
formul
pediatr
transplant
recipi
benefit
ad
cmv
hyperimmun
globulin
treat
cmv
diseas
remain
uncertain
judici
reduct
immunosuppress
import
compon
treatment
cmv
diseas
despit
success
treatment
cmv
infect
recur
onethird
solid
organ
recipi
incid
resist
sot
patient
receiv
prophylaxi
estim
ebv
ubiquit
human
herpesviru
abil
transform
immort
b
lymphocyt
result
lifelong
latent
infect
normal
host
prolifer
immort
b
cell
limit
cytotox
lymphocyt
ctl
respons
transplant
recipi
howev
immunosuppress
therapi
impair
respons
creat
potenti
uncontrol
lymphoprolifer
particularli
true
recipi
undergo
primari
infect
transplant
ebv
infect
associ
wide
spectrum
diseas
pediatr
transplant
patient
includ
asymptomat
seroconvers
nonspecif
viral
ill
mononucleosi
ptld
lymphoma
term
ebvassoci
ptld
gener
use
describ
heterogen
group
clinic
syndrom
associ
ebv
driven
lymphoprolifer
rang
benign
selflimit
form
polyclon
prolifer
true
malign
contain
clonal
chromosom
abnorm
diseas
may
nodal
extranod
local
dissemin
ptld
identifi
common
post
transplant
malign
pediatr
sot
patient
primari
ebv
infect
often
donorassoci
ebv
seroposit
donorseroneg
recipi
clearli
defin
risk
factor
develop
earli
ptld
month
transplant
children
therefor
consider
higher
risk
develop
ptld
adult
often
ebv
time
transplant
incid
ptld
also
depend
type
organ
transplant
small
intestin
transplant
recipi
highest
risk
pancrea
heart
lung
liver
transplant
recipi
moder
risk
recipi
kidney
transplant
rel
low
risk
high
index
suspicion
clinic
vigil
must
maintain
allow
time
evalu
ebv
diseas
ptld
increas
bodi
evid
support
measur
quantit
ebv
viral
load
use
pcr
peripher
blood
adjunct
earli
diagnosi
ebv
ptld
particularli
highest
risk
ongo
research
assist
develop
recommend
optim
monitor
protocol
ebv
diseaseptld
consid
sot
recipi
present
fever
mononucleosi
gastrointestin
disturb
lymphadenopathi
organomegali
less
often
ptld
present
focal
neurolog
symptom
allograft
dysfunct
diagnost
evalu
includ
thorough
histori
physic
examin
quantit
ebv
assay
radiolog
evalu
ct
scan
chest
abdomen
pelvi
addit
evalu
select
patient
gastrointestin
endoscopi
brain
imag
bone
marrow
biopsi
includ
clinic
indic
patholog
remain
gold
standard
diagnosi
classif
ptld
therefor
import
pursu
biopsi
suspici
lesion
node
case
ptld
associ
ebv
infect
gener
ebvneg
case
wors
prognosi
case
ebvrel
ptld
ebvneg
ptld
common
late
transplant
greater
year
reduct
immunosuppress
wide
accept
initi
strategi
manag
categori
ebv
diseas
optim
role
time
addit
therapi
antivir
agent
intraven
immunoglobulin
monoclon
antibodi
interferon
chemotherapi
remain
controversi
gener
goal
therapi
promot
regress
diseas
minim
patient
morbid
preserv
graft
function
clinic
recurr
ptld
estim
occur
approxim
case
typic
hsv
reactiv
occur
earli
sot
previous
seroposit
subject
antivir
prophylaxi
primari
infect
transmit
allograft
describ
rare
children
seroneg
may
acquir
viru
close
contact
wherea
hsv
infect
commonli
present
orolabi
diseas
dissemin
diseas
form
pneumon
esophag
hepat
may
occur
antivir
prophylaxi
patient
hsv
seroposit
first
month
transplant
gener
prevent
seriou
hsv
diseas
young
children
fulli
immun
risk
primari
vzv
infect
sot
increas
risk
develop
sever
skin
diseas
viscer
involv
enceph
pneumon
hepat
strongli
recommend
children
immun
vzv
transplant
recommend
suscept
children
expos
vzv
receiv
prophylaxi
varicella
zoster
immun
globulin
within
hour
exposur
howev
limit
avail
lead
recommend
intraven
immunoglobulin
oral
acyclovir
start
day
post
exposur
strategi
yet
fulli
studi
sever
diseas
hsv
vzv
treat
intraven
acyclovir
recent
recogn
herpesvirus
beta
herpesvirus
associ
diseas
transplant
particular
link
varieti
clinic
manifest
transplant
recipi
includ
pneumon
fever
enceph
myelosuppress
similar
cmv
thought
immunomodulatori
effect
postul
coinfect
cmv
promot
develop
cmv
diseas
gammaherpesviru
associ
kaposi
sarcoma
transplant
particularli
countri
high
seropreval
rate
infect
commun
acquir
respiratori
virus
increasingli
recogn
caus
morbid
graft
failur
mortal
transplant
recipi
influenza
parainfluenza
rsv
infect
common
caus
upper
respiratori
tract
infect
children
transplant
recipi
associ
increas
risk
progress
pneumonia
also
well
recogn
respiratori
viral
infect
predispos
patient
coinfect
particularli
bacteri
pneumonia
addit
immunocompromis
patient
tend
prolong
viral
shed
resolut
symptom
lung
transplant
recipi
respiratori
viral
infect
associ
reject
diagnosi
respiratori
viral
infect
establish
cultur
rapid
antigen
detect
pcr
monoclon
antibodi
test
nasopharyng
aspir
bronchoalveolar
lavag
specimen
risk
factor
sever
diseas
common
childhood
viral
infect
sot
includ
onset
infect
earli
transplant
augment
immunosuppress
reject
younger
age
prevent
respiratori
viral
infect
predomin
infect
control
measur
immun
influenza
administ
yearli
child
close
contact
household
contact
health
care
worker
prophylaxi
rsvspecif
monoclon
antibodi
palivizumab
recommend
highrisk
infant
younger
month
random
trial
conduct
evalu
use
palivizumab
sot
howev
expert
support
use
immunoprophylaxi
infant
less
year
age
receiv
transplant
rsv
season
adenoviru
infect
although
frequent
asymptomat
caus
wide
varieti
infecti
syndrom
especi
transplant
recipi
clinic
manifest
often
relat
type
transplant
rang
selflimit
fever
gastroenter
hemorrhag
cystiti
necrot
hepat
pneumonia
potenti
caus
lifethreaten
infect
adenoviru
third
import
viral
infect
follow
pediatr
liver
transplant
cyclosporin
one
seri
epidemiolog
less
well
character
sot
type
particularli
sever
earli
lung
transplant
may
associ
fatal
pneumon
adenoviru
infect
identifi
pediatr
intestin
transplant
recipi
mani
patient
thought
experienc
asymptomat
shed
adenoviru
stool
frequenc
symptomat
invas
diseas
remain
determin
popul
diagnosi
adenoviru
includ
cultur
antigen
detect
recent
pcr
assay
histolog
evalu
remain
gold
standard
diagnosi
invas
diseas
time
definit
treatment
adenoviru
infect
decreas
immunosuppress
remain
import
compon
therapi
role
antivir
agent
remain
elucid
anecdot
report
small
case
seri
bone
marrow
stem
cell
recipi
suggest
benefit
cidofovir
howev
varieti
dose
regimen
employ
control
trial
conduct
infect
polyomaviru
homini
type
better
known
bk
viru
bkv
typic
occur
childhood
latenc
occur
renal
urogenit
cell
serolog
evid
exposur
bkv
found
gener
popul
worldwid
asymptomat
reactiv
lowlevel
replic
viruria
occur
healthi
individu
renal
transplant
recipi
persist
highlevel
bkv
replic
associ
tubulointerstiti
nephriti
ureter
stenosi
pediatr
renal
transplant
recipi
pretranspl
bkv
seroneg
statu
associ
increas
risk
primari
infect
subsequ
bkv
nephropathi
definit
diagnosi
bkv
diseas
requir
histopatholog
confirm
optim
manag
bkv
diseas
establish
experi
antivir
therapi
anecdot
although
trial
low
dose
cidofovir
underway
judici
reduct
immun
suppress
activ
surveil
reject
usual
result
improv
donorderiv
infect
west
nile
viru
lymphocyt
choriomening
viru
lcmv
rabi
recent
describ
outbreak
sever
acut
respiratori
syndrom
sar
transplant
recipi
sever
rapidli
progress
diseas
report
higher
viral
burden
appear
present
transplant
patient
may
implic
increas
infect
patient
report
emphas
challeng
prevent
detect
transmiss
unusu
pathogen
transplant
posttranspl
period
bacteri
fungal
infect
problemat
transplant
prophylact
strategi
decreas
risk
earli
transplant
recent
year
multidrugresist
mdr
bacteria
emerg
mani
transplant
center
includ
gramposit
bacteria
methicillinresist
staphylococcu
aureu
vancomycinresist
enterococci
well
gramneg
bacteria
eg
mdr
pseudomona
aeruginosa
extendedspectrum
esbl
produc
enterobacteriacea
complic
surgic
invas
diagnost
procedur
indwel
cathet
prolong
hospit
stay
high
antimicrobi
use
contribut
nosocomi
infect
mdr
bacteria
sot
aggress
infect
control
measur
judici
use
antimicrobi
critic
protect
highli
suscept
transplant
recipi
transplant
recipi
also
risk
infect
caus
unusu
organ
nontubercul
mycobacteria
legionella
nocardia
speci
donorderiv
bacteri
infect
result
local
colon
unrecogn
bacteremia
predispos
recipi
metastat
bacteremia
andor
mycot
aneurysm
site
vascular
anastomosi
surveil
cultur
knowledg
local
antimicrobi
resist
pattern
use
guid
empir
antibiot
therapi
opportunist
fungal
infect
long
recogn
signific
complic
sot
recipi
major
fungal
infect
earli
transplant
caus
candida
aspergillu
speci
common
earli
lung
transplant
invas
candidiasi
primarili
relat
technic
aspect
surgeri
eg
liver
transplant
recipi
recipi
donor
allograft
colon
eg
lung
transplant
recipi
pulmonari
aspergillosi
dissemin
cn
likewis
aspergillosi
common
caus
brain
abscess
organ
transplant
recipi
cmv
infect
risk
factor
subsequ
aspergillu
infect
fungal
infect
develop
late
transplant
may
due
reactiv
organ
abl
establish
latenc
endem
fungihistoplasma
coccidioid
cryptococcu
less
frequent
children
adult
aspergillu
may
associ
chronic
lung
reject
valu
screen
assay
invas
fungal
infect
eg
galactomanan
pcr
yet
determin
pneumocysti
jiroveci
import
caus
pneumonia
immunocompromis
patient
pcp
case
occur
month
transplant
infrequ
widespread
use
prophylaxi
trimethoprimsulfamethoxazol
consid
prophylact
agent
choic
altern
agent
avail
includ
pentamidin
dapson
atovaquon
combin
therapi
clindamycin
pyrimethamin
notabl
breakthrough
pcp
infect
patient
receiv
altern
prophylact
regimen
report
often
atyp
toxoplasma
gondii
also
opportunist
pathogen
immunocompromis
individu
toxoplasmosi
sot
may
result
primari
infect
reactiv
latent
infect
greatest
risk
acquisit
gondii
infect
occur
seroneg
heart
transplant
recipi
seroposit
donor
although
post
transplant
toxoplasmosi
frequent
found
cardiac
transplant
also
report
occur
recipi
organ
clinic
symptom
usual
develop
within
intermedi
posttranspl
period
fever
may
clinic
manifest
dissemin
parasit
cn
may
lead
sign
symptom
meningoenceph
sepsislik
pictur
pneumonia
cutan
lesion
unusu
manifest
prophylact
administr
pyrimethamin
seroneg
recipi
heart
seroposit
donor
prevent
diseas
altern
prophylaxi
trimethoprimsulfamethoxazol
appear
protect
adult
cardiac
transplant
recipi
although
uncommon
infect
mycobacterium
tuberculosi
mtb
transplant
associ
substanti
morbid
mortal
frequenc
posttranspl
mtb
develop
countri
may
reach
among
sot
recipi
live
endem
area
commonli
mtb
result
reactiv
latent
infect
diseas
onset
intermedi
period
compar
normal
host
clinic
present
sot
higher
incid
dissemin
diseas
extrapulmonari
involv
manifest
includ
fever
unknown
origin
allograft
dysfunct
coinfect
pathogen
uncommon
treatment
mtb
sot
pose
special
challeng
potenti
interact
antimtb
drug
immunosuppress
medic
potenti
hepatotox
prophylaxi
isoniazid
indic
patient
evid
latent
mtb
infect
expert
recommend
screen
candid
administ
prophylaxi
posit
undergo
transplant
pretranspl
evalu
potenti
pediatr
recipi
donor
import
compon
transplant
process
purpos
includ
identif
condit
may
disqualifi
either
donor
recipi
recognit
latent
activ
infect
may
requir
therapi
transplant
infecti
diseas
screen
donor
recipi
may
influenc
type
monitor
prophylaxi
recipi
receiv
prevent
infect
transplant
final
pretranspl
evalu
opportun
provid
cohes
educ
infect
prevent
child
famili
tabl
addit
screen
potenti
donor
recipi
guid
clinic
suspicion
infect
sinc
vaccin
like
less
effect
transplant
pretranspl
evalu
provid
import
opportun
updat
immun
live
vaccin
given
least
week
date
transplant
